GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Forward Dividend Yield %

Vertex Pharmaceuticals (BSP:VRTX34) Forward Dividend Yield % : 0.00% (As of Apr. 30, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Vertex Pharmaceuticals Forward Dividend Yield %?

As of today (2024-04-30), the Forward Annual Dividend Yield of Vertex Pharmaceuticals is 0.00%.

As of today (2024-04-30), the Trailing Annual Dividend Yield of Vertex Pharmaceuticals is 0.00%.

BSP:VRTX34's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.45
* Ranked among companies with meaningful Forward Dividend Yield % only.

Vertex Pharmaceuticals's Dividends per Share for the three months ended in Dec. 2023 was R$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Vertex Pharmaceuticals's Forward Dividend Yield %

For the Biotechnology subindustry, Vertex Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Forward Dividend Yield % falls into.



Vertex Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Vertex Pharmaceuticals  (BSP:VRTX34) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Vertex Pharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals (BSP:VRTX34) Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals (BSP:VRTX34) Headlines

No Headlines